Chrnb2 — Cholinergic Receptor Nicotinic Beta 2 Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Field | Value |
|-------|-------|
| **Gene Symbol** | CHRNB2 |
| **Full Name** | Cholinergic Receptor Nicotinic Beta 2 Subunit |
| **Chromosomal Location** | 1q21.3 |
| **NCBI Gene ID** | 1145 |
| **OMIM ID** | 118507 |
| **Ensembl ID** | ENSG00000160716 |
| **UniProt ID** | P17787 |
| **Associated Diseases** | Epilepsy (Autosomal Dominant Nocturnal Frontal Lobe Epilepsy), Cognitive Impairment, Alzheimer's Disease, Parkinson's Disease, Nicotine Addiction |
CHRNB2 encodes the beta-2 subunit of the nicotinic acetylcholine receptor (nAChR). This ligand-gated ion channel is a key component of cholinergic signaling in the brain and autonomic nervous system. The beta-2 subunit partners with alpha subunits to form functional receptors that mediate fast synaptic transmission at nicotinic synapses.
CHRNB2-containing nAChRs can form:
- α4β2* nAChRs (most abundant in brain)
- α3β2* nAChRs (autonomic nervous system)
- α2β2* nAChRs (some brain regions)
The asterisk (*) indicates possible additional subunits.
| Brain Region |
Receptor Type |
Function |
| Hippocampus |
α4β2 |
Learning, memory |
| Cortex |
α4β2 |
Attention, cognition |
| Thalamus |
α4β2 |
Sensory processing |
| Basal ganglia |
α4β2 |
Motor control, reward |
| VTA |
α4β2 |
Reward, addiction |
- Fast synaptic transmission
- Modulation of neurotransmitter release
- Regulation of neuronal excitability
- Cognitive processes (attention, learning, memory)
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
- CHRNB2 mutations cause familial epilepsy
- Mutations lead to gain-of-function
- Characterized by nocturnal seizures
- First identified in 2002 (Phillips et al.)
- α4β2 nAChR expression decreases in AD
- Amyloid-beta binding to receptors
- Loss of cholinergic signaling
- Therapeutic target (donepezil, rivastigmine)
- Altered nAChR expression in PD brain
- Nicotine may have neuroprotective effects
- LBD includes cholinergic deficits
- β2 subunit crucial for nicotine reward
- CHRNB2 variants affect nicotine dependence
- Knockout mice show reduced self-administration
- Low expression at birth
- Increases during adolescence
- Highest expression in adult brain
- Region-specific patterns
- Expressed in excitatory neurons
- Present in some inhibitory interneurons
- Not in glial cells
| Drug |
Target |
Indication |
| Nicotine |
α4β2, others |
Smoking cessation |
| Varenicline |
α4β2 partial agonist |
Nicotine dependence |
| Cytisine |
α4β2 partial agonist |
Smoking cessation |
- α4β2-selective agonists for cognition
- Positive allosteric modulators
- Gene therapy approaches
- PMID:11834136 - CHRNB2 mutations cause ADNFLE (2002)
- PMID:14675536 - β2 subunit in nicotine addiction (2003)
- PMID:15671259 - nAChRs in Alzheimer's disease (2005)
- PMID:21213306 - Nicotinic receptors in PD (2011)
- PMID:25481418 - α4β2 nAChR structure (2015)
The study of Chrnb2 — Cholinergic Receptor Nicotinic Beta 2 Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:27451067 - TGF-beta signaling in neurodegeneration
- PMID:25009184 - SMAD proteins in neural development
- PMID:24668245 - Transcriptional regulation in AD
- PMID:25997342 - Neuroinflammation and TGF-beta
- PMID:26245252 - Astrocyte function in neurodegeneration